Overview

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Observational survey aiming to evaluate the tolerability of Aromasin and the ways in which it is used in clinical practice in France (as adjuvant endocrine therapy).
Details
Lead Sponsor:
Pfizer
Treatments:
Exemestane